2025-07-14 - Analysis Report
Okay, here's a report analyzing Johnson & Johnson (JNJ) based on the provided data.

## Johnson & Johnson (JNJ) Analysis

Johnson & Johnson is a global healthcare company that researches, develops, manufactures, and sells a broad range of products in the healthcare field.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 15.59%
*   **VOO Cumulative Return:** 95.46%
*   **Absolute Divergence:** -79.87%
*   **Relative Divergence:** 3.0 (On a scale where 0 is the minimum and 100 is the maximum divergence)

**Analysis:** JNJ has significantly underperformed the S&P 500 (VOO) over the analyzed period. The large negative divergence indicates substantial underperformance. The Relative Divergence of 3.0 suggests that JNJ's underperformance is near its worst levels compared to its historical divergence range.

| Year       | CAGR   | MDD    | Alpha   | Beta | Cap(B) |
|------------|--------|--------|---------|------|--------|
| 2015-2017  | 28.0%  | 56.1%  | -1.0%   | -0.0 | 336.1  |
| 2016-2018  | 8.0%   | 56.6%  | -10.0%  | 0.0  | 310.5  |
| 2017-2019  | 18.0%  | 56.6%  | -12.0%  | 0.7  | 350.9  |
| 2018-2020  | 12.0%  | 59.2%  | -8.0%   | 0.3  | 378.6  |
| 2019-2021  | 32.0%  | 59.6%  | -16.0%  | 0.2  | 411.6  |
| 2020-2022  | 7.0%   | 61.4%  | 5.0%    | 0.2  | 425.0  |
| 2021-2023  | -15.0% | 61.4%  | -33.0%  | 0.4  | 377.1  |
| 2022-2024  | -35.0% | 61.4%  | -61.0%  | 0.3  | 347.9  |
| 2023-2025  | -12.0% | 70.1%  | -59.0%  | 0.2  | 377.5  |

**Analysis:**
*   **CAGR:** CAGR(연평균 복합 성장률)은 2020-2022년 기간에 7%로 가장 낮고, 2019-2021년 기간에 32%로 가장 높습니다. 최근에는 2021-2023년, 2022-2024년, 2023-2025년에 걸쳐 음의 값을 보입니다.
*   **MDD:** MDD(최대 낙폭)는 56.1%에서 70.1% 사이에서 변동하며, 2023-2025년 기간에 가장 높은 낙폭을 나타냅니다.
*   **Alpha:** Alpha는 2020-2022년에 5%로 유일하게 양수 값을 보이며, 나머지 기간에는 음수 값을 나타냅니다. 특히 2022-2024년에는 -61%로 가장 낮은 값을 보입니다.
*   **Beta:** Beta는 0에서 0.7 사이의 값을 가지며, 시장 변동성에 대한 민감도가 낮은 편입니다.
*   **Cap(B):** 시가총액은 전반적으로 증가하는 추세를 보이다가 2021-2023년 이후 감소하는 경향을 나타냅니다.

### 2. Recent Stock Price Movements

*   **Current Price:** 156.90
*   **Last Market Data:** Price: 156.88, Previous Close: 156.86, Change: 0.01
*   **5-Day Moving Average:** 156.39
*   **20-Day Moving Average:** 154.22
*   **60-Day Moving Average:** 154.19

**Analysis:** The stock price is currently trading above its 5-day, 20-day, and 60-day moving averages, suggesting a short-term bullish trend. The last market data indicates a very slight increase from the previous close, which is not a significant change.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3294 (Low Risk)
*   **RSI:** 81.52 (Overbought)
*   **PPO:** 0.3
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Divergence Change:** 1.3 (+) (Short-term increase)
*   **Expected Return:** -976.0% (Long-term, relative to S&P 500)

**Analysis:**

*   **MRI:** The MRI indicates a "Low Risk" environment, which is generally positive.
*   **RSI:** The RSI is in overbought territory, which could suggest a potential pullback or consolidation in the near term.
*   **PPO:** PPO(Percentage Price Oscillator)는 두 이동평균선 간의 관계를 백분율로 나타내는 지표
*   **Hybrid Signal:** The hybrid signal suggests a cautious buy signal, recommending using 80% of available cash to purchase shares.
*   **Relative Divergence Change:**  A positive change in relative divergence indicates that JNJ's performance is improving relative to the S&P 500 in the short term, but from a very low base.
*   **Expected Return:** The significantly negative expected return (-976.0%) is highly concerning, suggesting potential long-term underperformance compared to the S&P 500.

### 4. Recent News & Significant Events

*   **[2025-07-11]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-10]:** Analysts discussing recent performance and outlook.
*   **[2025-07-13]:** Notable stock volatility.
*   **[2025-07-14]:** Market experts highlight both risks and opportunities, advising monitoring of news and announcements.

**Analysis:** The recent news suggests potential volatility and the need to stay informed about company-specific developments and broader market conditions affecting JNJ.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2024-07-25 | 1.95 | 22.45 B$   |
| 2024-05-01 | 1.35 | 21.38 B$   |
| 2025-04-23 | 1.35 | 21.38 B$   |

**Analysis:**

*   EPS가 2025-04-23에 4.57로 높게 나타났지만, 그 외에는 1~2 수준으로 낮게 유지되고 있습니다.
*   매출은 21.38B$에서 22.47B$ 사이에서 변동하며, 비교적 안정적인 수준을 유지하고 있습니다.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $21.89B   | 66.40%        |
| 2024-12-31 | $22.52B   | 68.35%        |
| 2024-09-30 | $22.47B   | 69.01%        |
| 2024-06-30 | $22.45B   | 69.40%        |
| 2024-03-31 | $21.38B   | 69.55%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE    |
|------------|-----------|--------|
| 2025-03-31 | $78.11B   | 14.08% |
| 2024-12-31 | $71.49B   | 4.80%  |
| 2024-09-30 | $70.16B   | 3.84%  |
| 2024-06-30 | $71.54B   | 6.55%  |
| 2024-03-31 | $70.02B   | 4.65%  |

**Analysis:**

*   **Revenue:** Revenue has been relatively stable, fluctuating between $21.38B and $22.52B.
*   **Profit Margin:** Profit margins are high, ranging from 66.40% to 69.55%, indicating strong profitability. However, there is a slight decreasing trend in recent quarters.
*   **Equity:** Equity has generally increased, especially in the most recent quarter.
*   **ROE (Return on Equity):** ROE has fluctuated, with a significant spike in the latest quarter (2025-03-31). This recent increase in ROE could be a positive sign.

### 7. Overall Summary and Conclusion

Based on the provided data, Johnson & Johnson (JNJ) presents a mixed picture:

*   **Underperformance:** JNJ has significantly underperformed the S&P 500 (VOO) over the analyzed period, with a large negative divergence in cumulative returns.
*   **Recent Stock Movement:** The stock price is trading above its short-term moving averages, suggesting a short-term bullish trend, but the RSI indicates an overbought condition.
*   **Risk & Signal:**  The MRI suggests a "Low Risk" environment, and the hybrid signal recommends a cautious buy.
*   **Concerning Expected Return:** The highly negative expected return (-976.0%) is a major red flag, indicating potential long-term underperformance.
*   **Recent Events:** Recent news suggests potential volatility.
*   **Earnings:** EPS가 2025-04-23에 4.57로 높게 나타났지만, 그 외에는 1~2 수준으로 낮게 유지되고 있습니다.
*   **Financials:** Profit margins are high and equity has generally increased, but ROE has fluctuated.

**Conclusion:**

While JNJ exhibits strong profitability and a low-risk market environment, the significant underperformance compared to the S&P 500 and the alarming negative expected return raise serious concerns. The recent earnings and news suggest potential volatility. Investors should closely monitor company-specific developments, broader market conditions, and any potential catalysts for improved performance before making investment decisions. The data suggests caution is warranted.
